Browse the corpus

Cephalosporins are β-lactam antimicrobials used to manage various infections caused by both gram-positive and gram-negative bacteria. The 5 generations of cephalosporins demonstrate efficacy in treating skin and soft tissue infections, pneumonia, meningitis, and other infections. Cefiderocol is a novel siderophore cephalosporin that exhibits remarkable antibacterial activity. This drug has been approved by the US Food and Drug Administration (FDA) to treat complicated urinary tract infections and ventilator-associated pneumonia caused by highly resistant gram-negative bacteria, including Klebsiella pneumonia, Proteus mirabilis, Escherichia coli, Pseudomonas aeruginosa, and Acinetobacter baumannii. Cefiderocol emerges as a promising therapeutic option for challenging infections, with literature reviews suggesting its potential in combating strains resistant to carbapenems. Importantly, cefiderocol is the only recently approved β-lactam agent exhibiting in vitro activity against carbapenem-resistant A baumannii (CRAB) isolates. According to the Infectious Diseases Society of America guidelines, cefiderocol should be reserved for cases of CRAB infections that remain unresponsive to other antibiotics or when intolerance to alternative agents prohibits their use. This activity provides clinicians with comprehensive insights into indications, mechanisms of action, contraindications, monitoring protocols, potential adverse drug reactions, and clinical toxicology associated with cephalosporins. This activity also provides healthcare professionals with essential knowledge and necessary tools to make informed decisions, promptly identify adverse effects, and optimize patient outcomes through vigilant monitoring and effective cephalosporin utilization, ensuring antibiotic therapy proficiency. Objectives: Identify the spectrum of activity of cephalosporins against both gram-positive and gram-negative bacteria. Screen patients for potential contraindications and drug interactions before initiating cephalosporin therapy. Implement appropriate dosing regimens and administration routes for cephalosporins based on the type and severity of infection. Coordinate with other healthcare team members to ensure timely and appropriate use of cephalosporins in multidisciplinary patient care plans. Access free multiple choice questions on this topic.

Signs and Symptoms of Overdose After conducting experiments on rabbits to test the effects of high-dosage cephalosporin, it has been discovered that the drug's impact on the mitochondria system of the kidney results in nephrotoxicity.[64] Cefepime overdose can result in seizures and encephalopathy. Studies show it to potentially result from cefepime crossing the blood-brain barrier and displaying concentration-dependent ϒ-aminobutyric acid (GABA) antagonism, which can also occur with toxic doses of penicillin G. Other studies show altered mental status and a triphasic wave discharge on electroencephalogram (EEG). Discontinuation of cefepime demonstrates normalization of mental status.[65][66] A study analyzed 511 severe adverse drug reaction reports on cephalosporins recorded in the French Pharmacovigilance database from 1987 to 2017. Patients, primarily older men with compromised renal function, experienced various central nervous system manifestations, including encephalopathy, confusional state, convulsions, and myoclonia. Cefepime and ceftriaxone were the most implicated cephalosporins.[67] Management of Overdose Management of neurotoxicity and seizures involves discontinuing the offending cephalosporin, providing supportive care, and initiating anticonvulsant therapy if necessary.[68]

Effective teamwork among healthcare professionals is vital for providing quality patient care. A shared goal, clear roles, and trust between the team members can increase efficiency. Clinicians should accurately diagnose, prescribe, and inform patients of adverse effects. Nurses should be aware of potential adverse drug reactions. Pharmacists can educate patients, provide information on adverse effects, and report potential interactions to clinicians. A recent study showed that pharmacist-led antimicrobial stewardship interventions, specifically focusing on antibiotics, led to lasting improvements such as increased blood culture collections, more frequent de-escalation of agents, and a significant reduction in hospital-acquired infections.[69] Patients should be advised to promptly communicate any unusual symptoms they may be experiencing to both the clinician and nurse. Through effective interprofessional teamwork, appropriate management of cephalosporin adverse drug reactions can occur, resulting in better patient outcomes. Adopting an interprofessional team-based approach that involves clinicians, infectious disease specialists, pharmacists, and patients is instrumental in achieving the desired therapeutic outcomes of cephalosporins.